Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Summary

The goal of this protocol is to isolate lymphatic endothelial cells lining human lymphatic malformation cyst-like vessels and foreskins using fluorescence-activated cell sorting (FACS). Subsequent cell culturing and expansion of these cells permits a new level of experimental sophistication for genetic, proteomic, functional and cell differentiation studies.

Abstract

Lymphatic system disorders such as primary lymphedema, lymphatic malformations and lymphatic tumors are rare conditions that cause significant morbidity but little is known about their biology. Isolating highly pure human lymphatic endothelial cells (LECs) from diseased and healthy tissue would facilitate studies of the lymphatic endothelium at genetic, molecular and cellular levels. It is anticipated that these investigations may reveal targets for new therapies that may change the clinical management of these conditions. A protocol describing the isolation of human foreskin LECs and lymphatic malformation lymphatic endothelial cells (LM LECs) is presented. To obtain a single cell suspension tissue was minced and enzymatically treated using dispase II and collagenase II. The resulting single cell suspension was then labelled with antibodies to cluster of differentiation (CD) markers CD34, CD31, Vascular Endothelial Growth Factor-3 (VEGFR-3) and PODOPLANIN. Stained viable cells were sorted on a fluorescently activated cell sorter (FACS) to separate the CD34^LowCD31^PosVEGFR-3^PosPODOPLANIN^Pos LM LEC population from other endothelial and non-endothelial cells. The sorted LM LECs were cultured and expanded on fibronectin-coated flasks for further experimental use.

Introduction

A major function of the lymphatic vascular system is to absorb lymph, an excess interstitial fluid containing lipids, proteins and cellular components, and conduct it to the blood venous system. A network of lymphatic capillaries directs lymph to the lymph nodes where it is screened for presence of foreign antigens, an important process in immune surveillance and deployment of white blood cells to neutralize foreign antigens.

The uni-directional lymphatic system starts in tissues with the initial lymphatic capillary, a unique structure with a discontinuous single layer of thin-walled flat endothelial cells with specialized cell junctions that permit lymph entry^1,2. These capillaries are attached to the neighboring connective tissue matrix via anchoring filaments to prevent vessel collapse in presence of increased interstitial pressure³. The initial lymphatic capillaries empty into collecting lymphatic capillaries that coalesce into larger lymphatic vessels or veins. In comparison to initial lymphatic capillary vessels, collecting lymphatic vessels have thicker vessel walls, paired lymphatic valves and are encased by a discontinuous basement membrane in which a few smooth muscle cells are embedded⁴. Coordinated opening and closure of lymphatic valves and contraction of smooth muscle cells facilitates flow of lymph³. In humans, the lymphatic veins from various regions of the body join to form lymphatic trunks which merge to form two lymphatic ducts: the thoracic duct and the right lymphatic duct. The thoracic duct drains lymph from the left side of the body and from the right side below the chest while the right lymphatic duct drains lymph from the right arm and right side of the head, neck, and thorax. Both ducts conduct lymph into the subclavian veins in the neck⁵.

Disorders of the lymphatic system are broadly grouped into acquired and congenital (Table 1). Examples of acquired conditions are lymphangitis and secondary lymphedema. Lymphangitis is an inflammation of a lymphatic vessel due to bacterial infection. The affected lymphatics dilate and fill with exudate containing polymorphonuclear cells. In skin, these lymphatics are visible as red, painful subcutaneous streaks often accompanied by enlargement of the associated draining lymph node (lymphadenitis)⁶. Secondary lymphedema arises as a consequence of damage or obstruction to the lymphatic vessel or lymph node obstruction. This leads to chronic progressive swelling due to accumulation of lymph distal to the damage or obstruction. In developed countries, secondary lymphedema is most commonly associated with malignancy where metastasizing tumors obstruct lymphatic vessels or regional lymph nodes, or as a consequence of anti-cancer therapy following surgical removal of lymph nodes, post-irradiation fibrosis and post-inflammatory thrombosis and scarring⁷. In other parts of the world, secondary lymphedema may be secondary to lymphatic obstruction caused by parasitic worms such as Wuchereria bancrofti⁶.

Disorders of Lymphatic Vascular System
Acquired	Congenital
Lymphadenitis Secondary lymphedema	Primary Lymphedema10	Sporadic Lymphatic Malformations13	Lymphatic Malformations Associated with Syndromes13
	e.g. Milroy Syndrome Meige Syndrome	Simple: Lymphatic malformations	e.g. Klippel-Tranaunay Syndrome Parks Weber Syndrome Sturge-Weber Syndrome
		Combined: Capillary-lymphatic malformations Capillary-lymphatic-venous malformation Capillary-lymphatic-arteriovenous malformation Capillary-lymphatic venous-arteriovenous malformation

Table 1. Overview of the disorders of lymphatic vascular system.

Congenital disorders of the lymphatic system include primary (idiopathic) lymphedema thought to be caused by genetic mutations, lymphangiectasia and anomalies of the lymphatic system^8,9. Primary lymphedema can be sporadic presumably caused by de novo mutations, or inherited. Lymphatic disorders can also be isolated or comprise part of a more generalized syndrome¹⁰. In the pediatric population, 97% of lymphedema is sporadic with abnormalities in lymphatic vessel structure that impair regional lymph drainage¹¹. Milroy disease is an example of primary lymphedema caused by mutation in the VEGFR-3 gene evident at birth or soon after¹². Although mostly familial condition, the Milroy disease can also be identified in infants without family history of Milroy disease³². The severity of any lymphedema is dependent on the amount of lymph production and ability to transport lymph back to venous circulation⁶.

Based on clinical presentation and in situ endothelial cell proliferation, anomalies of the lymphatic system are classified as lymphatic tumors or lymphatic malformations¹³. Kaposiform lymphangiomatosis is an example of an LEC tumor¹⁴. Lymphatic malformations are thought to arise during embryonic development and grow in proportion to the child^15,16. They rarely regress but can remain asymptomatic until trauma or infection precipitates rapid growth leading to clinical complications. The orderly structure of lymphatic network and conduction of lymph from the tissue to venous circulation described above is perturbed in lymphatic malformations which consist of localized collections of abnormal cystic structures filled with lymphatic fluid. While there is no clinical or experimental evidence that these cystic vessels are connected to the lymphatic circulation or that they contain functional lymphatic valves, their lymphatic identity is confirmed by expression of range of lymphatic cell markers such as PODOPLANIN, CD31, Lymphatic Vessel Endothelial Receptor 1 (LYVE-1), Prospero homeobox protein 1 (PROX-1) and VEGFR-3^15,17,18. These cystic structures can be either small (microcystic) or large (macrocystic), but most lymphatic malformations contain both microcystic and macrocystic components (Figure 1)¹⁶. Following surgery, injection sclerotherapy and/or radiofrequency ablation the lymphatic malformations often reoccur.

Figure 1. Morphology of human lymphatic vessels and lymphatic malformations. Normal human lymphatic (A) and lymphatic malformation vessels (B and C) labelled with antibody to PODOPLANIN (brown label, arrow). Human lymphatic malformation vessels are characterized by marked dilation and considerable variation in lumen size. These localized abnormal cystic structures can be either small (microcystic, *) (B) or large (macrocystic, #) (C). Most lymphatic malformations contain both microcystic and macrocystic components. Please click here to view a larger version of the figure.

Some investigators have suggested that lymphatic malformations represent a developmental disorder of lymphatic vasculature in which the LECs do not have abnormal growth potential but instead have failed to connect to the normal circulation¹⁹. However, we have found that the LM LECs proliferate faster and are more resistant to apoptosis than foreskin LECs¹⁵ suggesting that there is a primary defect in the LM LECs. When LM LECs are implanted in a mouse xenograft model, they form structures reminiscent of lymphatic malformations¹⁵. This supports a hypothesis that lymphatic malformations may be caused by one or more somatic mutations arising in LM LECs during fetal development. Indeed, recent reports have identified one such mutation in the p110α catalytic subunit of Phosphoinositide-3-Kinase (PIK3CA) gene²⁰.

Given the advances in DNA sequencing technology, relevant mutations could be more readily identified in isolated LM LECs, guiding future studies of these conditions. The isolation of viable LECs would facilitate comparisons between abnormal and normal LECs in assays such as migration, proliferation, tube forming ability and survival in response to reduced nutrient availability or pro-apoptotic agents¹⁵. Isolated LECs would further enable us to perform cell-specific gene expression and proteomic studies, to delineate new LEC subpopulations and discover novel pharmacological agents suitable for clinical management of lymphatic malformations.

We have previously published a LEC isolation method based on magnetic bead separation of LECs from neonatal foreskin and lymphatic malformations¹⁵. We reported a strategy of separating normal and diseased LECs from vascular endothelial cells based on the absence of CD34 expression, followed by subjecting CD34^Neg cell fraction to positive selection for CD31. However, this method was hampered by the presence of residual non-endothelial cells. This was independent of removing epidermis prior to subsequent connective tissue digestion. These contaminants generally proliferated more rapidly and thus eventually overgrew the endothelial cell cultures despite subsequent attempts to repeat LEC isolation. Indeed, an initial contamination of non-endothelial cells as low as 2% to 5% was sufficient to overwhelm the LEC population¹⁵. This prompted us to explore fluorescently activated cell sorting method as an option to improve LEC cell yield and purity. In addition, we used multi-parameter sorting to enhance the specificity of the LEC populations, adding VEGFR-3 and PODOPLANIN to the selection markers to identify CD34^LowCD31^PosVEGFR-3^PosPODOPLANIN^Pos LECs.

The rationale for selecting these markers was based on the reports that while LECs and blood vascular endothelial cells have many cell surface markers in common such as CD31, LECs show phenotypic variation in their expression of CD34, PODOPLANIN and VEGFR-3 cell surface marker when compared to blood vascular endothelial cells^21-23. CD31 is a 130 kDa transmembrane glycoprotein also known as platelet endothelial cell adhesion molecule 1 (PECAM-1). It is considered to be a pan-endothelial cell marker since it is expressed on all types of blood and lymphatic vessels^21,24,25. CD34 is 110-kDa transmembrane glycoprotein present on most hematopoietic progenitor and stem cells, vascular endothelial cells and some lymphatic vessels²⁶.

VEGFR-3, the receptor for vascular endothelial growth factors C and D, is initially present on the developing veins in the mouse embryo, but following lymphatic specification regulated by the transcription factors SRY-related HMG-box (SOX)-18, chicken ovalbumin upstream promoter transcription factor 2 (COUPTF-II) and PROX-1, VEGFR-3 venous expression is lost and it becomes restricted to embryonic LECs^25,27. PODOPLANIN, a 38 kDa membrane mucoprotein, is first noted on lymphatic vessels at approximately embryonic day 11 (~E11.0) of mouse embryonic development ²⁸ and whilst it is strongly expressed by microvascular lymphatic vessels, PODOPLANIN expression by macrocystic lymphatic endothelium in lymphatic malformations is more variable¹⁵. Flow cytometry experiments suggest that at least some CD34^HighCD31^Pos endothelial cells express the lymphatic marker PODOPLANIN²⁹. Although systematic evaluation of LYVE-1 and PODOPLANIN staining in human lymphatic malformations showed that both are effective at staining lymphatic malformation endothelium³⁰, in normal tissues, LYVE-1 was reported to be strongly present in the initial lymphatic capillary endothelium but reduced and even absent in the collecting lymphatic endothelium³¹. As our aim is to isolate both the initial and collecting lymphatic endothelial cells we have opted not to use LYVE-1 as part of our cell selection strategy. Finally, the decision to employ these markers was also based on the availability of antibodies that are used diagnostically for labelling lymphatic vessels for microscopic imaging, a feature that would permit correlation between flow cytometry and immunofluorescent studies.

This article will describe the tissue digestion method, cell staining and FACS settings required for successful isolation of CD34^LowCD31^PosVEGFR-3^PosPODOPLANIN^Pos LECs as well as CD34^HighCD31^PosVEGFR-3^PosPODOPLANIN^Pos endothelial cells from foreskin and lymphatic malformation tissue.

Protocol

Ethics statement: Ethical approval for collection of lymphatic malformation and foreskin tissues was obtained from the Human Research Ethics Committees at the Royal Children’s Hospital, Melbourne, Australia. Signed consent was received from patients’ parents prior to surgery. Tissue samples were collected from patients diagnosed with LMs undergoing surgical procedures as part of their clinical management and patients undergoing elective circumcision. All experiments were performed in accordance with guidelines of the National Health and Medical Research Council, Australia.

1. Preparation of Cell Suspension from Foreskin and Lymphatic Malformation Tissues

1. Buffers and Media Preparation.
   1. Prepare complete endothelial cell media using commercially available EGM-2 MV Bullet Kit by warming EGM-2 media and gently thawing the kit components in 37 °C water bath. In class II biosafety cabinet, aseptically add each component to the EGM-2 media. Once all components are added to the media, refer to this media as ‘complete endothelial cell media’. Use sterile 50 ml pipette to mix the contents prior to use.
      NOTE: All steps pertaining to cell culture are performed in a class II biohazard cabinet. All solutions are stored at 4 °C as per manufacturers’ instructions and are warmed to room temperature prior to use. The complete endothelial cell media, cell culture buffers and enzyme solutions are warmed at 37 °C for 20 min prior to use.
   2. Supplement complete endothelial cell media with 50 ng/ml VEGF-C. Aliquot the supplemented endothelial cell media into 50 ml sterile tubes and store at 4 °C until use. The media is stable for at least 4 weeks when stored at 4 °C.
   3. Prepare calcium and magnesium free phosphate-buffered saline (PBS) by dissolving 8.752 g NaCl, 1.416 g Na₂HPO₄.2H₂O and 0.395 g KH₂PO₄ in 1,000 ml of water. Adjust pH to 7.4. Filter sterilize PBS using 0.22 μm filter and store at 4 °C. Prior to use add antibiotic/antimycotic solution (used at 1:100).
   4. To prepare human fibronectin, dissolve 1 mg of fibronectin in 10 ml of sterile water. Store reconstituted solution in 100 μl aliquots at -20 °C. On the day of use add 10 ml of sterile PBS to 100 μl of fibronectin aliquot (to give a final working concentration of 10 μg/ml).
   5. For the enzyme media, prepare a solution containing 0.04% Dispase II, 0.25% Collagenase II and 0.01% DNase I in sterile PBS. First, weigh dispase and collagenase, place in a sterile 50 ml tube, add the required volume of PBS and incubate for 30 min with shaking at 37 °C to dissolve. Once dissolved, filter sterilize (0.22 μm filter) dispase/collagenase solution in biosafety hood. Aseptically add the DNase I. Store the enzymatic solution at 37 °C until use.
      NOTE: DNase I is a commercial cell culture grade reagent available as sterile lyophilized powder.

2. Preparation of Cell Suspension from Foreskin and Lymphatic Malformations

1. Weigh a 50 ml tube containing 10 ml of DMEM/2% antibiotic antimycotic solution. This tube will be used for tissue collection.
2. Following surgical removal of lymphatic malformation and foreskin tissues, aseptically add tissue specimen to the tube and transfer on ice to the cell culture laboratory.
3. Weigh the tube containing the tissue and calculate tissue weight. Use this weight to calculate the volume of enzymatic solution needed to digest the tissue.
4. In a Class II biosafety cabinet, use sterile forceps to transfer the tissue and media into a 100 mm tissue culture dish. Use sterile scissors to finely mince the tissue into ~1 mm³ pieces.
5. Transfer minced tissue mixed with media into a 50 ml tube containing an additional 10 ml of sterile DMEM/2% antibiotic antimycotic solution. Mix by inversion to re-suspend the tissue. Centrifuge the sample at 300 x g for 5 min.
6. Remove the supernatant. Based on tissue weight, add 1 ml of pre-warmed (37 °C) collagenase II/DNase I/ Dispase II digestion solution per 100 mg of minced tissue. Generally, use 10 ml of enzyme solution for approximately 1 g of minced tissue.
7. Incubate the tissue in a 37 °C incubator for 20-90 min with constant shaking at 200 rpm. At the end of this period, ensure that nearly all of the tissue is digested into fine fragments.
   NOTE: Exposure of the cells to collagenase and dispase at the time of isolation from the primary tissues influences cell survival. We have found empirically that most neonatal foreskin samples optimally require 20-30 min of digestion, whereas fibrotic lymphatic malformation samples may require 60-90 min of digestion. LM LEC yields are influenced by the amount of fibrosis present, more fibrous tissue yielding fewer cells, possibly due to deleterious effects of prolonged exposure to collagenase II and dispase II.
8. Following digestion, transfer the tube to the biosafety cabinet and pass the digested tissue solution through a 70 μm strainer placed into a sterile 50 ml tube. Using 3 ml syringe piston with rubber plunger, grind down the remaining tissue until only small traces of extracellular matrix are observed.
9. Wash the cell strainer with a volume of endothelial cell medium equivalent to the volume of dissociating enzyme medium to recover cells stuck to sieve and to inactivate the enzymes. For example, for 2 ml of dissociating enzyme medium to digest the minced tissue, add 2 ml of endothelial cell medium to inactivate the enzymes.
10. Centrifuge the cell solution at 300 x g for 5 min and aspirate the supernatant. R>e-suspend the cells in 10 ml of PBS. Centrifuge cells at 300 x g for 5 min, remove the supernatant then repeat cell wash twice. >Resuspend the cell pellet in 20 ml of endothelial cell medium. Count cells using trypan blue then seed 2 x 10>⁶ cells in 150 cm>² flask pre-coated with fibronectin in a final volume of 20 ml of endothelial cell medium. Culture at 37 °C in a 5% CO>₂ in humidified air incubator.>
    NOTE: It is expected that 75%-90% of nucleated cells survive tissue digestion as estimated by trypan blue exclusion. The initial cell count reflects all nucleated cells in the cell suspension (i.e. keratinocytes, leukocytes, macrophages, connective tissue cells and blood vessel cells). The cell count at 5-7 days reflects cells that have attached, survived and proliferated during cell culture. Coating tissue culture flasks with fibronectin also improves subsequent LEC and LM LEC survival.
11. After overnight incubation, wash away unbound cells in three washes with PBS/1% antibiotic-antimycotic solution and add fresh endothelial cell medium. Carry out three washes to effectively remove unbound cells and red blood cells present in the flask. Change media every second day. Cells will be ~80% confluent after 5-7 days.

3. Antibody Staining of Cells for Lymphatic Endothelial Cell Surface Markers for Flow Cytometry

1. After the cells have reached 80% confluence, aspirate medium and rinse cells with PBS.
2. Detach adherent cells by incubating cells with 7 ml of cell detachment solution such as Accutase per 150 cm² flask for 5-7 min at 37 °C.
3. Harvest detached cells, inactivate the cell detachment solution by adding 3 volumes of endothelial cell medium and transfer the cell suspension to a new sterile tube.
4. Centrifuge the cells at 300 x g for 5 min.
5. Aspirate supernatant and re-suspend the cells in 5 ml of PBS. Centrifuge cells at 300 x g for 5 min, remove the supernatant then repeat cell wash. Re-suspend the cells in 5 ml of PBS.
6. Count the number of viable cells. Mix 10 μl of cell suspension with 90 μl of 0.4% trypan blue. Transfer 10 μl of this suspension to hemocytometer for counting.
   NOTE: The final cell yield will depend on the sample size processed. The usual cell yield per 150 cm² flask ranges from 7 x 10⁵ to 1.2 x 10⁶ of viable cells.
7. Prepare the antibody solutions for cell staining.
   NOTE: The following dilutions were titrated for staining 1 x 10⁶ in a staining volume of 100 μl.
   1. Dilute PE conjugated mouse anti human VEGFR-3 (1:50); PE-Cy7 conjugated mouse anti human conjugated CD34 (1:200); APC-conjugated mouse anti human CD31 (1:100) and Alexa 488-conjugated rat anti human PODOPLANIN (1:200) in total volume of 100 μl sterile 5% FBS/PBS solution per tissue sample. Following preparation of antibody solution, keep on ice until use. Similarly prepare diluted isotype control antibody mixture to facilitate setting of flow cytometry gates.
8. To reduce nonspecific binding of the antibodies, centrifuge cells at 300 x g for 2 min, remove supernatant then suspend the cells in 100 μl sterile 5% FBS/PBS solution per sample to be stained. Incubate cells on ice for 20 min at 4 °C.
9. Centrifuge cells at 300 x g for 5 min, remove supernatant then re-suspend cells in the conjugated antibody cocktail. Also stain a smaller aliquot of cells (1 x 10⁵) in 100 μl isotype control antibody mixture. Incubate cells on ice for 20 min.
10. To remove the unbound antibody, add 2 ml of 2% FBS/PBS solution and centrifuge the cells at 300 x g for 5 min. Aspirate the supernatant and repeat the wash.
11. Resuspend the cell pellet for the isotype control and the antibody stained sample to be sorted in 300 μl of 0.5 mg/ml propidium iodide/2% FBS/PBS solution. Place tubes on ice until sorting.

4. Cell Sorting

1. Use the following materials to set up the instrument; alignment beads such as commercially available fluorescent particles, phosphate-buffered saline based sheath fluid and drop delay beads, such as Accudrop fluorescent beads.
2. Isolate the purified human LECs on a multi-parameter fluorescence-activated cell sorting instrument. Set up the instrument and align as per manufacturer’s recommendations. In addition, run single stain compensation controls with each sort to generate the compensation matrix and to thus eliminate substantial bleed through of the emission of fluorochromes such as PE into the PE-Cy channel.
   NOTE: A higher proportion of the FACS sorted cells survive the isolation if a 100 μm nozzle is used and cells are sorted into endothelial cell medium.

5. Cell Culture Post FACS Sorting

1. Following sorting, centrifuge cells at 300 x g for 5 min. Aspirate the supernatant and resuspend the cells in 5-10 ml of media (depending on the flask used to seed the cell). If less than 50,000 cells are sorted, the cells are cultured in fibronectin coated 25 cm² flask.
2. Otherwise culture the cells in 75 cm² fibronectin-coated flask at 37 °C in a 5% CO₂, air humidified incubator. Change media after 2 days.
   NOTE: Cell media is changed every second day because prolonging the time between media changes appears to favor survival of the non-endothelial cells. We validate the lymphatic endothelial cell phenotype using immunohistochemical detection of markers: PROX-1, VEGFR-3, Podoplanin, CD34 and CD31 when the cells are first split for further expansion¹⁵.

Results

Following initial tissue digestion, after 24 hours in culture of unfractionated samples, distinct endothelial cell colonies can be observed (Figure 2A) together with fibroblast-like cells and smooth muscle cells. Following sorting and after 24 hours in cell culture, the CD34^LowCD31^PosVEGFR-3^PosPodoplanin^Pos cells attach and show typical cobblestone morphology (Figure 2B and C). Using the FACS method described above, we are able...

Discussion

LECs play an important role in maintaining fluid homeostasis, immune response to foreign antigens and absorption and transport of some nutrients. LEC homeostasis can be affected by disease processes such as bacterial infections and tumor metastasis, but LECs can also develop somatic mutations that result in formation of dysfunctional lymphatic vessels and significant morbidity for affected patients. To gain more understanding of lymphatic malformation etiology through in vivo implantation and ex vivo ex...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
DMEM	Life Technologies (Gibco)	11965-092	Used to collect tissue samples from the operating theatre.
EGM-2 MV Bullet Kit	Lonza	CC-3202	EGM-2 MV Bullet Kit contains 500 ml of EBM-2 media and human EGF, hydrocortisone, gentamycin (GA-1000), fetal bovine serum (FBS), VEGF, human FGF-b, R3-IGF-1 and ascorbic acid.
VEGF-C	R&D Systems	2179-VC-025	Complete endothelial cell media is supplemented with 50 ng/ml VEGF-C
Antibiotic-antimycotic solution (100x)	Life Technologies (Gibco)	15240-062	This solution contains 10,000 U/ml of penicillin, 10,000 mg/ml of streptomycin and 25 mg/ml of Fungizone antimycotic. Use at 1:100 dilution.
Fibronectin from human plasma	Sigma-Aldrich	F2006	Used at 10 mg/ml concentrations. It can be re-used for up to 1 month if kept at 4 °C and maintained sterile. Use 7 ml to coat 150 cm2 flask.
StemPro Accutase Cell dissociation reagent	Life Technologies (Gibco)	A11105-01	StemPro®Accutase® is used at 0.05 ml per cm2 to cover the entire surface area of the flask. Using lesser volumes may result in incomplete cell detachment.
0.4% Trypan Blue dye	Life Technologies (Gibco)	15250-061	Used as a viability stain.
Dispase II	Roche Applied Biosciences	4942078001	Used at 0.04%
Collagenase II	Worthington Lab	4176	Used at 0.25%
DNase I	Roche Applied Biosciences	11284932001	Used at 0.01%
70 mm nylon cell strainers	BD Falcon	352350
[header]
PE-conjugated VEGFR-3 clone 9D9F9, clone WM59	BioLegend	356204	Used at 1:50 dilution
PE-Cy7-conjugated CD34, clone 581	BioLegend	343516	Used at 1:200 dilution
APC-conjugated mouse anti human CD31, clone WM59	BioLegend	303116,	Used at 1:100 dilution
Alexa 488-conjugated rat anti human Podoplanin, clone NC-80.	BioLegend	337006	Used at 1:200 dilution
PE-conjugated mouse IgG1, k isotype, clone MOPC-21	BioLegend	400112	Used at 1:50 dilution
PE-Cy7-conjugated mouse IgG1, k isotype, clone MOPC-21	BioLegend	400126	Used at 1:200 dilution
APC-conjugated mouse IgG1, k isotype, clone MOPC-21	BioLegend	400120	Used at 1:100 dilution
Alexa 488-conjugated mouse IgG2a, k isotype, clone RATK2758	BioLegend	400525	Used at 1:200 dilution